Peptomyc, a spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and ICREA, has closed its second round of investment for €11.4 million, led by the Italian fund Aurora Science. The operation also involved the CDTI and existing investors such as Alta Life Sciences and HealthEquity, as well as business angels and employees.
This funding will enable Peptomyc, a CataloniaBio & HealthTech member, to advance its lead candidate OMO103 through to the preliminary results of Phase I clinical trials. OMO103 has already been proven safe and to have anti-tumour activity in several types of experimental cancer models. The first patients will begin treatment at hospitals in Barcelona and Madrid in the first quarter of 2021.
Peptomyc co-founder and CEO Laura Soucek highlights: "The industrial knowledge in biopharma and translational medicine of Aurora Science executives will be very important to the success of our molecule."
Guido Guidi, president of Aurora Science, acknowledges that Peptomyc "is a company with cutting-edge science and outstanding potential to bring benefits to patients."
Photo: Scientists Marie-Eve Beaulieu and Laura Soucek founded Peptomyc in 2014 at Barcelona.
You may also be interested in:
Want to know more about Peptomyc? We recommend this video of CataloniaBio & HealthTech interviewing them:
Comments